Seres therapeutics reports third quarter 2021 financial results and provides business updates

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today reported third quarter 2021 financial results and provided business updates. “we have made considerable progress across our organization, highlighted by the achievement of target enrollment in our investigational ser-109 recurrent c. difficile infection (rcdi) open-label study, and continued preparations for a bla filing with the u.s. food and drug administration (fda). a
MCRB Ratings Summary
MCRB Quant Ranking